Article
Medicine, General & Internal
Eric Anderson, Alexis LeVee, Sungjin Kim, Katelyn Atkins, Michelle Guan, Veronica Placencio-Hickok, Natalie Moshayedi, Andrew Hendifar, Arsen Osipov, Alexandra Gangi, Miguel Burch, Kevin Waters, May Cho, Samuel Klempner, Joseph Chao, Mitchell Kamrava, Jun Gong
Summary: The study reveals that neoadjuvant chemoradiation (nCRT) is associated with the highest rate of pathologic complete response, while neoadjuvant and adjuvant chemotherapy (CTTU) is associated with the best overall survival.
Editorial Material
Oncology
Bryan J. Schneider, Andrew C. Chang
Summary: This article reviews the findings of a randomized clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma. The study suggests that postoperative immunotherapy represents a significant treatment option for these aggressive malignancies.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Editorial Material
Medicine, General & Internal
David H. Ilson
Summary: Esophageal cancer is a major cause of cancer-related illness and death worldwide, often presenting with locally advanced or metastatic disease due to lack of effective screening or early detection. Esophageal squamous-cell carcinoma is the most common histologic type globally, especially in high-incidence areas like East Asia, while adenocarcinoma dominates in the West. Surgical outcomes for esophageal squamous-cell cancer patients in 1980 highlighted the significant challenge in treating esophageal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Jinming Shi, Wenzhe Kang, Yuan Tang, Ning Li, Liming Jiang, Lin Yang, Shulian Wang, Yongwen Song, Yueping Liu, Hui Fang, Ningning Lu, Shunan Qi, Bo Chen, Yexiong Li, Yantao Tian, Jing Jin
Summary: This study compares the survival benefit between adjuvant chemoradiotherapy (CRT) and chemotherapy (CT) in patients with stage III gastric or gastroesophageal junction (GEJ) cancer after D2/R0 resection. The results show that the addition of adjuvant chemoradiotherapy significantly improves overall survival and reduces regional recurrence in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yu Mei, Xijia Feng, Tienan Feng, Min Yan, Zhenggang Zhu, Tian Li, Zhenglun Zhu
Summary: This retrospective study examined the role of adjuvant chemotherapy (ACT) in patients with pT2N0M0 gastric cancer who underwent radical resection. The study found that ACT was associated with higher 5-year overall survival and disease-specific survival rates. Patients with pT2N0M0 gastric cancer, regardless of high-risk factors, may be suitable for ACT.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Kristen E. Rhodin, Vignesh Raman, Austin Eckhoff, Annie Liu, John Creasy, Daniel P. Nussbaum, Dan G. Blazer
Summary: The study found that fragmented care for stage II/III gastric cancer patients is associated with poorer outcomes, including reduced preferred perioperative treatment and decreased survival rates. Factors associated with coordinated care include residence in metropolitan areas and treatment at academic and high-volume centers.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
C. -H Kung, C. Jestin Hannan, G. Linder, J. Johansson, M. Nilsson, J. Hedberg, M. Lindblad
Summary: The study found a correlation between patient survival and regional resection rates, with higher resection rates benefiting overall survival for gastric cancer patients who undergo surgery.
Article
Oncology
Meifeng Li, Haifeng Chen, Jun He, Jiajing Xie, Jie Xia, Hui Liu, Yidan Shi, Zheng Guo, Haidan Yan
Summary: The study identified a signature consisting of 34 gene pairs that can accurately classify which patients may benefit from 5-FU-based ACRT, aiding clinicians in tailoring more effective treatments for gastric cancer.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Axel Stenmark Tullberg, Henri A. J. Puttonen, Martin Sjostrom, Erik Holmberg, S. Laura Chang, Felix Y. Feng, Corey Speers, Lori J. Pierce, Dan Lundstedt, Fredrika Killander, Emma Nimeus, Aniko Kovacs, Per Karlsson
Summary: The study demonstrates that an antitumoral immune infiltrate in the primary tumor is associated with a reduced risk of breast cancer recurrence and less benefit from adjuvant radiotherapy. These findings suggest potential implications for decisions regarding postoperative radiotherapy in early breast cancer.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Xin Wang, Dong-Bing Zhao, Lin Yang, Yihebali Chi, Hong Zhao, Li-Ming Jiang, Jun Jiang, Yuan Tang, Ning Li, Wen-Yang Liu, Li-Zhou Dou, Shuang-Mei Zou, Li-Yan Xue, Jian-Song Ren, Yan-Tao Tian, Xu Che, Chun-Guang Guo, Xiao-Feng Bai, Yue-Min Sun, Shu-Lian Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Ye-Xiong Li, Jing Jin
Summary: This study compared the efficacy and safety of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced gastric cancer. The results showed that neoadjuvant chemoradiotherapy resulted in better tumor regression but did not improve the R0 resection rate. There was no significant difference in postoperative complications between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Huiwen Lu, Yimeng Sun, Zirui Zhu, Junqiao Yao, Huimian Xu, Rui Huang, Baojun Huang
Summary: This study found that adjuvant chemoradiotherapy offers significant survival benefits to advanced gastric cancer patients compared with chemotherapy alone, with similar nausea/vomiting side effects but an increased risk of neutropenia. It is strongly recommended for patients without preoperative treatment or with positive surgical margins to undergo chemoradiotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Caroline Fong, Edwina Johnston, Naureen Starling
Summary: Gastric cancer requires a multimodality approach to achieve optimal curative rates. Preferences for neoadjuvant and adjuvant approaches vary across the globe, but a multimodal approach provides clear survival benefits compared to surgery alone. However, the completion rates of adjuvant therapy are low, highlighting the need for patient selection optimization and individualized treatment strategies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Marianne C. Kalff, Isolde Vesseur, Wietse J. Eshuis, David J. Heineman, Freek Daams, Donald L. van der Peet, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz
Summary: This study evaluated the clinicopathologic predictors of textbook outcome in esophageal cancer surgery and found that achieving textbook outcome was associated with better overall and disease-free survival. The study highlighted the correlation between textbook outcome and long-term survival, emphasizing the importance of pursuing textbook outcome.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Michelle R. Ju, James-Michael Blackwell, Herbert J. Zeh, Adam C. Yopp, Sam C. Wang, Matthew R. Porembka
Summary: Higher annual hospital gastrectomy volume is associated with improved surgical outcomes, with 17 cases/year identified as a clinically meaningful distinction between high-volume (HV) and low-volume (LV) centers. Treatment at a high-volume gastrectomy center leads to increased likelihood of adequate nodal examination, R0 resection, and decreased 30- and 90-day postoperative mortality.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Sang Cheul Oh, Young Soo Park, Taeil Son, Mi Ran Jung, Mi Hwa Heo, Hark Kyun Kim, ChoHyun Park, Chang Hak Yoo, Jin-Hyuk Choi, Dae Young Zang, You Jin Jang, Ji Young Sul, Jong Gwang Kim, Beom Su Kim, Seung-Hoon Beom, Sang Hee Cho, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyun Ki Kim, Moon-Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh
Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Riddhita De, Rinku Sutradhar, Paul Kurdyak, Suriya Aktar, Jason D. Pole, Nancy Baxter, Paul C. Nathan, Sumit Gupta
Summary: The study found that survivors of adolescent and young adult cancers face higher mental health risks, especially those treated in adult medical centers. While the absolute risk of psychotic disorder-associated severe events was low, survivors were at an increased risk. Therefore, long-term mental health surveillance and research into effective interventions during or after cancer treatment are warranted.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Koen Degeling, Nancy N. Baxter, Jon Emery, Mark A. Jenkins, Fanny Franchini, Peter Gibbs, G. Bruce Mann, Grant McArthur, Benjamin J. Solomon, Maarten J. IJzerman
Summary: The study shows that the COVID-19 pandemic has delayed cancer diagnosis and treatment, impacting survival outcomes and healthcare costs. Based on Australian data, even a conservative once-off 3-month delay is predicted to result in 88 excess deaths and $12 million excess healthcare costs.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
Maria C. Cusimano, Sarah E. Ferguson, Rahim Moineddin, Maria Chiu, Suriya Aktar, Ning Liu, Nancy N. Baxter
Summary: Bilateral salpingo-oophorectomy at the time of benign hysterectomy can significantly reduce the incidence and death rate of ovarian cancer, especially for postmenopausal women aged 50 or above, with a higher degree of risk reduction.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2022)
Article
Oncology
Hallie Coltin, Adam Rapoport, Nancy N. Baxter, Chenthila Nagamuthu, Paul C. Nathan, Jason D. Pole, Franco Momoli, Sumit Gupta
Summary: Adolescents and young adults with cancer may receive high-intensity end-of-life care, with pediatric care and rural residence associated with higher odds of ICU death.
Review
Health Care Sciences & Services
Arlinda Ruco, Fahima Dossa, Jill Tinmouth, Diego Llovet, Jenna Jacobson, Teruko Kishibe, Nancy Baxter
Summary: This study evaluated the effectiveness of social media and mHealth interventions in promoting cancer screening. The results suggest that mHealth interventions have a promising role in increasing participation in cancer screening, while further research is needed for social media interventions.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2021)
Article
Oncology
Dalia Kagramanov, Rinku Sutradhar, Cindy Lau, Zhan Yao, Jason D. Pole, Nancy N. Baxter, Sumit Gupta, Paul C. Nathan
Summary: The study found that specialized survivor clinics (SCCs) were associated with higher adherence, but few survivors received such care, and the proportion decreased over time. Interventions are needed to improve LTFU attendance and promote surveillance adherence.
Article
Oncology
Nancy N. Baxter, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M. Morris, Erika Ruiz-Garcia, Y. Nancy You, Jeffrey A. Meyerhardt
Summary: The study aims to develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Alina Zgardau, Joel G. Ray, Nancy N. Baxter, Chenthila Nagamuthu, Alison L. Park, Sumit Gupta, Paul C. Nathan
Summary: Female survivors of pediatric cancer have a lower likelihood of achieving pregnancy and, once pregnant, are at higher risk for preterm birth and maternal complications.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Marian S. Wettstein, Nancy N. Baxter, Rinku Sutradhar, Muhammad Mamdani, Pham Song, Syed R. Qadri, Kathy Li, Ning Liu, Theodorus van der Kwast, Thomas Hermanns, Girish S. Kulkarni
Summary: This study investigated the rates of re-resection in T1 bladder cancer patients within 2-6 weeks after initial transurethral resection of the bladder tumor (TURBT). The study found that the re-resection rates increased steadily from 2001 to 2015, regardless of the guideline revision in April 2008. There were variations in the uptake of the guideline-endorsed intervention among different groups of surgeons.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Gastroenterology & Hepatology
Nancy N. Baxter, Marcia Facey, Arlinda Ruco, Natalie A. Baker, Anne Sorvari, Amina Benmessaoud, Catherine Dube, Linda Rabeneck, Jill Tinmouth
Summary: This study describes the challenges faced by organized colorectal cancer screening programs and the adaptive measures taken during the early stages of the COVID-19 pandemic. The study highlights the importance of quick decision-making, flexible management of screening capacity, and ethical considerations in effectively responding to crises.
BMJ OPEN GASTROENTEROLOGY
(2022)
Article
Oncology
Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng
Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Matthew Castelo, Lawrence Paszat, Bettina E. Hansen, Adena S. Scheer, Neil Faught, Lena Nguyen, Nancy N. Baxter
Summary: The study found that some younger colorectal cancer patients experience prolonged delays from symptom presentation to treatment, with the longest delay occurring between the first investigation and diagnosis.
BMJ OPEN GASTROENTEROLOGY
(2022)
Review
Gastroenterology & Hepatology
Colin Sue-Chue-Lam, Matthew Castelo, Amina Benmessaoud, Teruko Kishibe, Diego Llovet, Christine Brezden-Masley, Amy Y. X. Yu, Jill Tinmouth, Nancy N. Baxter
Summary: A scoping review found limited research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy. There was significant variation in the characteristics and results of the included studies across different countries. Future research should focus on underinvestigated interventions and develop consensus-based guidelines for study design.
BMJ OPEN GASTROENTEROLOGY
(2023)
Article
Oncology
Colin Sue-Chue-Lam, Christine Brezden-Masley, Rinku Sutradhar, Amy Y. X. Yu, Nancy N. Baxter
Summary: This study examined the association between the duration of oxaliplatin-containing adjuvant chemotherapy and mortality in stage III colon cancer. The results showed that compared to receiving a full course of treatment, patients who received only 50% of the course had slightly higher overall mortality and cancer-specific mortality, but the differences were not significant.
Review
Oncology
Matthew Castelo, Colin Sue-Chue-Lam, Lawrence Paszat, Adena S. Scheer, Bettina E. Hansen, Teruko Kishibe, Nancy N. Baxter
Summary: Outcome disparities between younger and older adults with colorectal cancer may be explained by clinical delays. This study found that younger adults experienced longer delays in diagnosis and were more likely to be diagnosed at advanced stages. However, younger adults had shorter delays in receiving treatment after diagnosis.